Very recently it has been demonstrated that utilizing the tumor‐penetrating abilities of dimeric IgA, intracellular mutated oncodrivers‐specific dimeric IgA antibodies could target and expel the oncoproteins out of PIGR+ cancer cells.27 Here, CD79A is linked to neoplasm.